The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Editorial: Emerging metabolic and transcriptomic signature of PNPLA3 associated NASH
Hepatology. 2021 Feb 5. doi: 10.1002/hep.31735. Online ahead of print.
Debanjan Dhar1, Rohit Loomba123
Author information
1Division of Gastroenterology, University of California San Diego, La Jolla, CA, 92093, USA, La Jolla.
2NAFLD Research Center, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
3Division of Epidemiology, Department of Family Medicine and Public Heath, University of California San Diego, La Jolla, CA, 92093, USA, La Jolla.
Abstract
Non-alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease worldwide. About 30% of the adult population in the United States (US) is afflicted with NAFLD. Approximately 20-25% of NAFLD patients have the progressive sub-type of NAFLD that is termed as Non-alcoholic Steatohepatitis (NASH). The cardinal features of NASH on liver histology include steatosis, lobular inflammation, ballooning with or without peri-sinusoidal fibrosis.